Suggested remit - To appraise the clinical and cost effectiveness of lenadogene nolparvovec within its marketing authorisation for treating Leber's hereditary optic neuropathy
Status In progress
Process STA 2018
ID number 1410

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
01 September 2020 In progress. Topic is in progress
01 September 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of lenadogene nolparvovec for treating Leber hereditary optic neuropathy. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
25 September 2018 - 23 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance